Skip to main content

Rezolute, Inc. (RZLT)

NASDAQ: RZLT · IEX Real-Time Price · USD
6.50 0.00 (0.00%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap100.23M
Revenue (ttm)n/a
Net Income (ttm)-20.90M
Shares Out8.35M
EPS (ttm)-2.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume72,358
Open6.50
Previous Close6.50
Day's Range6.36 - 6.60
52-Week Range5.86 - 21.11
Beta3.76
AnalystsBuy
Price Target25.40 (+290.8%)
Est. Earnings DateOct 27, 2021

About RZLT

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema....

IndustryBiotechnology
Founded2010
CEONevan Elam
Employees26
Stock ExchangeNASDAQ
Ticker SymbolRZLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Rezolute stock is "Buy." The 12-month stock price forecast is 25.40, which is an increase of 290.77% from the latest price.

Price Target
$25.40
(290.77% upside)
Analyst Consensus: Buy

News

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent ...

REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for me...

1 week ago - GlobeNewsWire

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Dire...

REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for me...

1 week ago - GlobeNewsWire

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of C...

Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism

1 month ago - GlobeNewsWire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated w...

1 month ago - GlobeNewsWire

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to c...

1 month ago - GlobeNewsWire

Rezolute Added to Russell Microcap® Index

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to ch...

3 months ago - GlobeNewsWire

Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs

REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated wit...

5 months ago - GlobeNewsWire

Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalan...

5 months ago - GlobeNewsWire

Rezolute to Participate in Upcoming Investor Conferences in March

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company's CEO and Founder, will be presenting at the following upcomi...

7 months ago - GlobeNewsWire

Rezolute Reports Second Quarter Fiscal 2021 Financial Results

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.

8 months ago - GlobeNewsWire

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Dia...

RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME

9 months ago - GlobeNewsWire

Rezolute Announces Change of Transfer Agent

REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of...

9 months ago - GlobeNewsWire